|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:CTNNA3-MGMT (FusionGDB2 ID:HG29119TG4255) |
Fusion Gene Summary for CTNNA3-MGMT |
Fusion gene summary |
Fusion gene information | Fusion gene name: CTNNA3-MGMT | Fusion gene ID: hg29119tg4255 | Hgene | Tgene | Gene symbol | CTNNA3 | MGMT | Gene ID | 29119 | 4255 |
Gene name | catenin alpha 3 | O-6-methylguanine-DNA methyltransferase | |
Synonyms | ARVD13|VR22 | - | |
Cytomap | ('CTNNA3')('MGMT') 10q21.3 | 10q26.3 | |
Type of gene | protein-coding | protein-coding | |
Description | catenin alpha-3alpha-T-cateninalpha-catenin-like proteincatenin (cadherin-associated protein), alpha 3 | methylated-DNA--protein-cysteine methyltransferase6-O-methylguanine-DNA methyltransferaseO-6-methylguanine-DNA-alkyltransferaseO6-methylguanine-DNA methyltransferasemethylguanine-DNA methyltransferase | |
Modification date | 20200313 | 20200315 | |
UniProtAcc | Q9UI47 | P16455 | |
Ensembl transtripts involved in fusion gene | ENST00000373744, ENST00000433211, ENST00000373735, ENST00000545309, | ||
Fusion gene scores | * DoF score | 16 X 15 X 3=720 | 19 X 11 X 7=1463 |
# samples | 16 | 18 | |
** MAII score | log2(16/720*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(18/1463*10)=-3.02286095780881 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CTNNA3 [Title/Abstract] AND MGMT [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | CTNNA3(68381450)-MGMT(131334505), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | CTNNA3-MGMT seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. CTNNA3-MGMT seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | MGMT | GO:0043066 | negative regulation of apoptotic process | 24147153 |
Tgene | MGMT | GO:2000781 | positive regulation of double-strand break repair | 24147153 |
Fusion gene breakpoints across CTNNA3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across MGMT (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | BRCA | TCGA-AO-A03V-01A | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
Top |
Fusion Gene ORF analysis for CTNNA3-MGMT |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000373744 | ENST00000462672 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
5CDS-intron | ENST00000433211 | ENST00000462672 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
Frame-shift | ENST00000433211 | ENST00000306010 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
In-frame | ENST00000373744 | ENST00000306010 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
intron-3CDS | ENST00000373735 | ENST00000306010 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
intron-3CDS | ENST00000545309 | ENST00000306010 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
intron-intron | ENST00000373735 | ENST00000462672 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
intron-intron | ENST00000545309 | ENST00000462672 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000373744 | CTNNA3 | chr10 | 68381450 | - | ENST00000306010 | MGMT | chr10 | 131334505 | + | 3020 | 1374 | 0 | 2009 | 669 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000373744 | ENST00000306010 | CTNNA3 | chr10 | 68381450 | - | MGMT | chr10 | 131334505 | + | 0.002778667 | 0.99722135 |
Top |
Fusion Genomic Features for CTNNA3-MGMT |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
CTNNA3 | chr10 | 68381449 | - | MGMT | chr10 | 131334504 | + | 0.000376188 | 0.9996238 |
CTNNA3 | chr10 | 68381449 | - | MGMT | chr10 | 131334504 | + | 0.000376188 | 0.9996238 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for CTNNA3-MGMT |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:68381450/chr10:131334505) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CTNNA3 | MGMT |
FUNCTION: May be involved in formation of stretch-resistant cell-cell adhesion complexes. {ECO:0000303|PubMed:11590244}. | FUNCTION: Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | CTNNA3 | chr10:68381450 | chr10:131334505 | ENST00000373744 | - | 9 | 17 | 325_379 | 458 | 896.0 | Coiled coil | Ontology_term=ECO:0000255 |
Hgene | CTNNA3 | chr10:68381450 | chr10:131334505 | ENST00000373744 | - | 9 | 17 | 74_111 | 458 | 896.0 | Coiled coil | Ontology_term=ECO:0000255 |
Hgene | CTNNA3 | chr10:68381450 | chr10:131334505 | ENST00000433211 | - | 10 | 18 | 325_379 | 458 | 896.0 | Coiled coil | Ontology_term=ECO:0000255 |
Hgene | CTNNA3 | chr10:68381450 | chr10:131334505 | ENST00000433211 | - | 10 | 18 | 74_111 | 458 | 896.0 | Coiled coil | Ontology_term=ECO:0000255 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CTNNA3-MGMT |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>20297_20297_1_CTNNA3-MGMT_CTNNA3_chr10_68381450_ENST00000373744_MGMT_chr10_131334505_ENST00000306010_length(transcript)=3020nt_BP=1374nt ATGTCAGCTGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGCAGGTCCAAACATTCACCGTGGAGAAGCTACTGGAGCCTCTC ATAATCCAGGTTACCACACTTGTAAACTGTCCCCAGAACCCTTCCAGCAGGAAAAAAGGACGTTCGAAAAGAGCCAGTGTCCTTCTAGCT TCTGTGGAGGAAGCAACTTGGAATTTATTAGACAAGGGAGAGAAGATTGCCCAGGAAGCTACAGTTTTAAAGGATGAGCTTACGGCTTCA CTTGAGGAAGTTCGCAAAGAAAGTGAAGCTCTGAAAGTATCAGCTGAGAGATTTACAGATGACCCCTGTTTTCTCCCAAAAAGGGAGGCT GTGGTTCAAGCTGCCCGTGCCTTGCTGGCTGCGGTGACGAGACTCCTTATCCTTGCGGACATGATTGATGTCATGTGCCTCTTGCAACAT GTGTCAGCTTTTCAAAGGACATTTGAGTCTCTCAAAAATGTTGCCAACAAATCTGACCTCCAGAAAACCTACCAGAAGCTTGGGAAGGAG CTGGAAAATTTGGATTATTTAGCCTTCAAACGTCAGCAGGACTTAAAATCTCCAAATCAGAGAGATGAAATTGCAGGAGCCCGAGCTTCA CTGAAGGAGAACTCTCCCCTCTTGCATTCAATTTGTTCAGCTTGTTTGGAGCATTCTGATGTTGCTTCCCTCAAAGCAAGCAAGGACACA GTTTGTGAAGAAATTCAGAATGCTCTCAATGTAATTTCAAATGCTTCACAAGGGATCCAGAATATGACAACCCCACCAGAACCTCAGGCA GCAACCCTGGGAAGTGCCCTTGATGAGCTGGAGAATTTAATTGTCCTGAATCCACTCACAGTAACTGAGGAGGAAATACGACCATCACTA GAGAAACGCCTTGAAGCCATTATCAGTGGGGCTGCTCTGCTGGCGGATTCTTCATGTACGAGGGACTTACACCGAGAGCGGATTATCGCA GAATGCAACGCCATTCGCCAGGCTCTTCAGGATCTGCTTTCAGAGTACATGAACAACGCTGGAAAAAAAGAAAGGAGTAATACCCTGAAT ATTGCTTTAGACAACATGTGTAAGAAGACAAGAGACCTTCGCAGACAGCTCCGCAAGGCTATTATAGATCATGTGTCAGACTCTTTCCTG GATACGACAGTCCCTCTTTTGGTTCTCATTGAAGCTGCTAAGAATGGCCGGGAAAAGGAAATAAAAGAATATGCTGCGATATTTCATGAA CACACCAGCAGGCTTGTAGAGGTGGCAAATCTTGCTTGTTCCATGTCAACAAATGAAGATGGAATTAAAATTGTCAAAATTGCAGCCAAT CATTTGGAAACCTTGTGTCCACAGGTACTTGGAAAAATGGACAAGGATTGTGAAATGAAACGCACCACACTGGACAGCCCTTTGGGGAAG CTGGAGCTGTCTGGTTGTGAGCAGGGTCTGCACGAAATAAAGCTCCTGGGCAAGGGGACGTCTGCAGCTGATGCCGTGGAGGTCCCAGCC CCCGCTGCGGTTCTCGGAGGTCCGGAGCCCCTGATGCAGTGCACAGCCTGGCTGAATGCCTATTTCCACCAGCCCGAGGCTATCGAAGAG TTCCCCGTGCCGGCTCTTCACCATCCCGTTTTCCAGCAAGAGTCGTTCACCAGACAGGTGTTATGGAAGCTGCTGAAGGTTGTGAAATTC GGAGAAGTGATTTCTTACCAGCAATTAGCAGCCCTGGCAGGCAACCCCAAAGCCGCGCGAGCAGTGGGAGGAGCAATGAGAGGCAATCCT GTCCCCATCCTCATCCCGTGCCACAGAGTGGTCTGCAGCAGCGGAGCCGTGGGCAACTACTCCGGAGGACTGGCCGTGAAGGAATGGCTT CTGGCCCATGAAGGCCACCGGTTGGGGAAGCCAGGCTTGGGAGGGAGCTCAGGTCTGGCAGGGGCCTGGCTCAAGGGAGCGGGAGCTACC TCGGGCTCCCCGCCTGCTGGCCGAAACTGAGTATGTGCAGTAGGATGGATGTTTGAGCGACACACACGTGTAACACTGCATCGGATGCGG GGCGTGGAGGCACCGCTGTATTAAAGGAAGTGGCAGTGTCCTGGGAACAAGCGTGTCTGCCCTTTCTGTTTCCATATTTTACAGCAGGAT GAGTTCAGACGCCCGCGGTCCTGCACACATTTGTTTCCTTCTCTAACGCTGCCCTTGCTCTATTTTTCATGTCCATTAAAACAGGCCAAG TGAGTGTGGAAGGCCTGGCTCATGTTGGGCCACAGCCCAGGATGGGGCAGTCTGGCACCCTCAGGCCACAGACGGCTGCCATAGCCGCTG TCCAGGGCCAGCTAAGGCCCATCCCAGGCCGTCCACACTAGAAAGCTGGCCCTGCCCCATCCCCACCATGCCTCCCTTCCTGGCTGTGTC CATGGCTGTGATGGCATTCTCCACTCAGCAGTTCCTAGCATCCCACACCCAGGTCTCACTGAAAGAAAGGGGAACAGGCCATGGCAGTCA GTGCTTACAGAGGTTTTCTAGCTTTGTTTCCTACCTGCCAAAAAGGCTAATGCAAGATGCATCCACTTATGGTCTGTATCAGGTGAATAG AAAATAACCATTTGCCAAGATTTGGAAAGACAGAGAGCTCTCTGGACACGGGTTCGATGGAGCTTGCACCTCTCTGAGAGCTGAAGTCAA GTCTCACCCTCTCTCCATACTCCCTGGCCTAGTGTGCTCTGGGCAGCAGGTAGGAAGGGACAGGGACCTCTCATCTCAAGGGCTGCCCCA AAGGGCCCTCAGGGACCATGGGCCTGTTAGGACCCCAGCACCCCAGTGTCGATCCTGGAAGTCAAAGGTCACGACTGTGGGGGGCCAGCT CATGTCACTGATGGCAGCAGGCAGGGTTTCCAGCATGGGCGGTGCGCTGCTGTCTGATACTTCATTATTGTGTTGTCATCCTAGCTGTAT >20297_20297_1_CTNNA3-MGMT_CTNNA3_chr10_68381450_ENST00000373744_MGMT_chr10_131334505_ENST00000306010_length(amino acids)=669AA_BP=458 MSAETPITLNIDPQDLQVQTFTVEKLLEPLIIQVTTLVNCPQNPSSRKKGRSKRASVLLASVEEATWNLLDKGEKIAQEATVLKDELTAS LEEVRKESEALKVSAERFTDDPCFLPKREAVVQAARALLAAVTRLLILADMIDVMCLLQHVSAFQRTFESLKNVANKSDLQKTYQKLGKE LENLDYLAFKRQQDLKSPNQRDEIAGARASLKENSPLLHSICSACLEHSDVASLKASKDTVCEEIQNALNVISNASQGIQNMTTPPEPQA ATLGSALDELENLIVLNPLTVTEEEIRPSLEKRLEAIISGAALLADSSCTRDLHRERIIAECNAIRQALQDLLSEYMNNAGKKERSNTLN IALDNMCKKTRDLRRQLRKAIIDHVSDSFLDTTVPLLVLIEAAKNGREKEIKEYAAIFHEHTSRLVEVANLACSMSTNEDGIKIVKIAAN HLETLCPQVLGKMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQCTAWLNAYFHQPEAIEE FPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGNPKAARAVGGAMRGNPVPILIPCHRVVCSSGAVGNYSGGLAVKEWL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CTNNA3-MGMT |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CTNNA3-MGMT |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | MGMT | P16455 | DB14548 | Zinc sulfate, unspecified form | Stabilization | Small molecule | Approved|Experimental |
Tgene | MGMT | P16455 | DB01593 | Zinc | Small molecule | Approved|Investigational | |
Tgene | MGMT | P16455 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
Tgene | MGMT | P16455 | DB14533 | Zinc chloride | Stabilization | Small molecule | Approved|Investigational |
Tgene | MGMT | P16455 | DB00151 | Cysteine | Small molecule | Approved|Nutraceutical |
Top |
Related Diseases for CTNNA3-MGMT |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | CTNNA3 | C0004096 | Asthma | 1 | CTD_human |
Hgene | CTNNA3 | C0013146 | Drug abuse | 1 | CTD_human |
Hgene | CTNNA3 | C0013170 | Drug habituation | 1 | CTD_human |
Hgene | CTNNA3 | C0013222 | Drug Use Disorders | 1 | CTD_human |
Hgene | CTNNA3 | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
Hgene | CTNNA3 | C0038580 | Substance Dependence | 1 | CTD_human |
Hgene | CTNNA3 | C0038586 | Substance Use Disorders | 1 | CTD_human |
Hgene | CTNNA3 | C0236969 | Substance-Related Disorders | 1 | CTD_human |
Hgene | CTNNA3 | C0740858 | Substance abuse problem | 1 | CTD_human |
Hgene | CTNNA3 | C1510472 | Drug Dependence | 1 | CTD_human |
Hgene | CTNNA3 | C1832931 | ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2 | 1 | ORPHANET |
Hgene | CTNNA3 | C3810138 | ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13 | 1 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | CTNNA3 | C4316881 | Prescription Drug Abuse | 1 | CTD_human |
Tgene | C0334588 | Giant Cell Glioblastoma | 4 | CTD_human;ORPHANET | |
Tgene | C0017638 | Glioma | 3 | CTD_human | |
Tgene | C0259783 | mixed gliomas | 3 | CTD_human | |
Tgene | C0555198 | Malignant Glioma | 3 | CTD_human | |
Tgene | C0017636 | Glioblastoma | 2 | CTD_human | |
Tgene | C0206726 | gliosarcoma | 2 | ORPHANET | |
Tgene | C1621958 | Glioblastoma Multiforme | 2 | CTD_human | |
Tgene | C0006118 | Brain Neoplasms | 1 | CTD_human | |
Tgene | C0023418 | leukemia | 1 | CTD_human | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
Tgene | C0026640 | Mouth Neoplasms | 1 | CTD_human | |
Tgene | C0027540 | Necrosis | 1 | CTD_human | |
Tgene | C0032927 | Precancerous Conditions | 1 | CTD_human | |
Tgene | C0153381 | Malignant neoplasm of mouth | 1 | CTD_human | |
Tgene | C0153633 | Malignant neoplasm of brain | 1 | CTD_human | |
Tgene | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human | |
Tgene | C0282313 | Condition, Preneoplastic | 1 | CTD_human | |
Tgene | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human | |
Tgene | C0750974 | Brain Tumor, Primary | 1 | CTD_human | |
Tgene | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human | |
Tgene | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human | |
Tgene | C1168401 | Squamous cell carcinoma of the head and neck | 1 | CTD_human | |
Tgene | C1449861 | Micronuclei, Chromosome-Defective | 1 | CTD_human | |
Tgene | C1449862 | Micronuclei, Genotoxicant-Induced | 1 | CTD_human | |
Tgene | C1527390 | Neoplasms, Intracranial | 1 | CTD_human | |
Tgene | C2314896 | Familial Atypical Mole Melanoma Syndrome | 1 | ORPHANET |